Dr. Christopher Fuller, M.D.
What this data tells you about Dr. Fuller
Dr. Christopher Fuller is an ophthalmology in Lubbock, TX, with 19 years in practice. Based on federal Medicare data, Dr. Fuller performed 63,918 Medicare services across 4,415 unique beneficiaries.
Between the years covered by Open Payments, Dr. Fuller received a total of $61,731 from 37 pharmaceutical and/or device companies across 275 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fuller is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) | 51,790 | $28 | $81 |
| Retinal imaging (OCT scan) | 3,014 | $29 | $100 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 2,432 | $120 | $331 |
| Eye injection for retinal disease | 1,686 | $87 | $1,045 |
| Comprehensive eye exam, established patient | 1,035 | $82 | $200 |
| Eye exam, established patient, focused | 945 | $60 | $200 |
| Aflibercept eye injection (Eylea) | 665 | $677 | $2,199 |
| Comprehensive eye exam, new patient | 443 | $105 | $275 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 337 | $144 | $401 |
| Injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mg | 270 | $411 | $1,111 |
| Injection, brolucizumab-dbll, 1 mg | 258 | $242 | $733 |
| Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg | 247 | $355 | $899 |
| Unclassified drugs | 235 | $1,765 | $5,643 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 156 | $224 | $513 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 76 | $93 | $285 |
| Unclassified biologics | 53 | $1,101 | $2,650 |
| Compounded drug, not otherwise classified | 51 | $71 | $162 |
| Removal of eye fluid (vitreous) between lens and retina | 50 | $662 | $4,000 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 30 | $784 | $5,000 |
| 2d ultrasound scan of eye tissue and structures | 26 | $37 | $305 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 25 | $880 | $5,700 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 24 | $865 | $6,000 |
| Removal of membrane of retina | 21 | $869 | $5,500 |
| Injection, bevacizumab, 10 mg | 20 | $47 | $143 |
| Extended exam of the back part of the eye with retinal drawing | 17 | $18 | $105 |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 12 | $174 | $615 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (48%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in ophthalmology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for ophthalmology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Fuller is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and high industry engagement (speaking/promotional, top 5%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Fuller experienced with eye injection (vabysmo/faricimab)?
Does Dr. Fuller receive payments from pharmaceutical companies?
How do Dr. Fuller's costs compare to other ophthalmologys in Lubbock?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology